NUTEX HEALTH REPORTS RESTATED FIRST QUARTER 2025 FINANCIAL RESULTS
Rhea-AI Summary
NUTEX HEALTH (NASDAQ: NUTX) reported restated Q1 2025 results for the quarter ended March 31, 2025, including a 214.0% increase in total revenue to $211.8M and net income attributable to Nutex of $21.2M versus a $0.4M loss in Q1 2024. EBITDA was $51.5M and Adjusted EBITDA was $72.8M. The company recorded $27.6M of stock-based compensation (≈99% related to under-construction and ramping hospitals).
The restatement corrected non-cash classifications (stock-based compensation reclassified from equity to liabilities, related-party payables reclassified to equity, $2.9M moved to short-term investments, and accrued income tax expense increased $2.4M). Total liabilities rose by $19.6M (4.0%), total equity declined $19.6M (7.1%), and net income for the period increased by $6.6M (14.9%) on the restated basis. Cash and cash equivalents were $84.7M and net cash from operating activities was $51.0M.
Positive
- Total revenue +214.0% to $211.8M
- Net income attributable to Nutex $21.2M vs $(0.4)M
- EBITDA $51.5M (+624.7%) and Adjusted EBITDA $72.8M
- Net cash from operations $51.0M and cash balance $84.7M
Negative
- Restatement increased total liabilities by $19.6M (4.0%) and reduced equity by $19.6M (7.1%)
- One-time stock-based compensation expense of $27.6M (99% related to under-construction hospitals) increases non-cash expense and potential dilution
News Market Reaction – NUTX
In the Nov 19 session, NUTX gained 13.09%, reflecting a significant positive market reaction. Argus tracked a peak move of +30.4% during that session. Argus tracked a trough of -2.6% from its starting point during tracking. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
-
Total revenue of
$211.8 million $67.5 million 214.0% -
Net income attributable to Nutex Health Inc. of
$21.2 million $0.4 million $21.6 million -
Diluted income per share of
$3.33 $0.08 -
EBITDA of
$51.5 million $7.1 million 624.7% -
Adjusted EBITDA of
$72.8 million $(0.4) million $73.2 million -
Net cash from operating activities of
$51.0 million - The Company believes its arbitration efforts through the Independent Dispute Resolution (IDR) process have resulted in an increase in fair and reasonable payments from insurance companies
First Quarter 2025 Restatement Background
As previously disclosed in Form 8-K filed on August 21, 2025, the Audit Committee of the Board of Directors of Nutex Health, after consultation with the Chief Financial Officer, concluded that the Company's previously issued condensed consolidated unaudited financial statements as of and for the three months ended March 31, 2025 contained in the originally filed Form 10-Q should be restated for the items described below. The major balance sheet accounts affected by these non-cash adjustments are as follows:
- Corrected the classification of non-cash, stock-based compensation obligations totaling
$20.7 million - Reclassified related-party accounts payable balances of
$3.5 million - Reclassified
$2.9 million - Increased accrued income tax expense by
$2.4 million
These adjustments as of March 31, 2025, when compared to the previously issued financial statements, result in an overall net increase to liabilities, a similar decrease to equity and an increase in net income. Total liabilities as of March 31, 2025 increased by
Financial highlights for the three months ended March 31, 2025 (as restated):
- Total revenue increased
$144.3 million $211.8 million $67.5 million 214.0% . Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by186.5% in 2025 compared to 2024. - Total stock-based compensation expense for the three months ended March 31, 2025 was
$27.6 million $0.1 million 99% of total stock-based compensation expense of$27.6 million - Operating income for the three months ended March 31, 2025 was
$80.7 million $1.5 million $79.2 million - Net income attributable to Nutex Health for the three months ended March 31, 2025 of
$21.2 million $0.4 million $21.2 million $27.6 million $0.4 million - EBITDA attributable to Nutex Health of
$51.5 million $7.1 million 624.7% . - Adjusted EBITDA attributable to Nutex Health of
$72.8 million $(0.4) million - Total visits at the Hospital Division were 48,269 for the three months ended March 31, 2025, as compared to 40,068 for the same period in 2024, an increase of 8,201 or
20.5% . Visits at mature hospitals increased by5.3% in the three months ended March 31, 2025 as compared to the same period in 2024. - Net cash from operating activities of
$51.0 million - As of March 31, 2025, the Company had total assets of
$761.9 million $84.7 million $21.7 million
Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.
"We are excited to provide yet another solid quarter with
"The great momentum that we started in 2024 is continuing into the first quarter of 2025. We are now seeing more consistent financial results stemming from a combination of volume growth and operational efficiency, with more fair and reasonable payments from the arbitration process. We would like to thank our team of physicians and team members nationwide for working in alignment to get us to where we are this quarter," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.
For more details on the Company's restated financial results for the three months ended March 31, 2025, please refer to our Amended Quarterly Report on Form 10-Q/A filed with the
|
NUTEX HEALTH INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
|
||||
|
(In thousands, except share and per share amounts) |
|
March 31, 2025 |
|
December 31, 2024 |
|
Assets |
|
(As Restated) |
|
|
|
Current assets: |
|
|
|
|
|
Cash and cash equivalents |
|
$ 84,729 |
|
$ 40,640 |
|
Restricted short-term investment |
|
2,941 |
|
2,941 |
|
Accounts receivable |
|
295,082 |
|
232,449 |
|
Accounts receivable - related parties |
|
4,258 |
|
3,602 |
|
Inventories |
|
3,118 |
|
2,850 |
|
Prepaid expenses and other current assets |
|
11,389 |
|
9,997 |
|
Total current assets |
|
401,517 |
|
292,479 |
|
Property and equipment, net |
|
76,431 |
|
77,933 |
|
Operating right-of-use assets |
|
27,466 |
|
27,872 |
|
Financing right-of-use assets |
|
216,193 |
|
218,889 |
|
Intangible assets, net |
|
15,205 |
|
15,530 |
|
Goodwill, net |
|
13,919 |
|
13,919 |
|
Deferred tax assets |
|
10,487 |
|
7,987 |
|
Other assets |
|
698 |
|
711 |
|
Total assets |
|
$ 761,916 |
|
$ 655,320 |
|
|
|
|
|
|
|
Liabilities and Equity |
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Accounts payable |
|
$ 19,836 |
|
$ 9,614 |
|
Accounts payable - related parties |
|
2,141 |
|
806 |
|
Lines of credit |
|
7,126 |
|
3,554 |
|
Current portion of long-term debt |
|
13,635 |
|
14,395 |
|
Operating lease liabilities, current portion |
|
2,103 |
|
2,080 |
|
Financing lease liabilities, current portion |
|
8,027 |
|
7,705 |
|
Accrued arbitration expenses |
|
51,803 |
|
47,742 |
|
Accrued income tax expense |
|
46,130 |
|
26,533 |
|
Accrued stock-based compensation |
|
20,739 |
|
16,356 |
|
Accrued expenses and other current liabilities |
|
24,639 |
|
25,440 |
|
Total current liabilities |
|
196,179 |
|
154,225 |
|
Long-term debt, net |
|
21,733 |
|
22,466 |
|
Operating lease liabilities, net |
|
30,350 |
|
30,617 |
|
Financing lease liabilities, net |
|
258,387 |
|
259,479 |
|
Total liabilities |
|
506,649 |
|
466,787 |
|
|
|
|
|
|
|
Commitments and contingencies (Note 9) |
|
|
|
|
|
|
|
|
|
|
|
Equity: |
|
|
|
|
|
Common stock, |
|
6 |
|
6 |
|
Additional paid-in capital |
|
512,701 |
|
489,409 |
|
Accumulated deficit |
|
(335,759) |
|
(356,976) |
|
Nutex Health Inc. equity |
|
176,948 |
|
132,439 |
|
Noncontrolling interests |
|
78,319 |
|
56,094 |
|
Total equity |
|
255,267 |
|
188,533 |
|
Total liabilities and equity |
|
$ 761,916 |
|
$ 655,320 |
|
NUTEX HEALTH INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
|
||||
|
|
|
Three Months Ended March 31, |
||
|
(In thousands, except share and per share amounts) |
|
2025 |
|
2024 |
|
|
|
(As Restated) |
|
|
|
Revenue: |
|
|
|
|
|
Hospital division |
|
$ 203,947 |
|
$ 60,029 |
|
Population health management division |
|
7,842 |
|
7,424 |
|
Total revenue |
|
211,789 |
|
67,453 |
|
|
|
|
|
|
|
Operating costs and expenses: |
|
|
|
|
|
Payroll |
|
34,860 |
|
27,003 |
|
Contract services |
|
38,655 |
|
11,319 |
|
Medical supplies |
|
3,801 |
|
5,322 |
|
Depreciation and amortization |
|
5,092 |
|
4,186 |
|
Other |
|
11,043 |
|
9,466 |
|
Total operating costs and expenses |
|
93,451 |
|
57,296 |
|
|
|
|
|
|
|
Gross profit |
|
118,338 |
|
10,157 |
|
|
|
|
|
|
|
Corporate and other costs: |
|
|
|
|
|
Stock-based compensation |
|
27,642 |
|
49 |
|
General and administrative expenses |
|
10,035 |
|
8,658 |
|
Total corporate and other costs |
|
37,677 |
|
8,707 |
|
|
|
|
|
|
|
Operating income (loss) |
|
80,661 |
|
1,450 |
|
|
|
|
|
|
|
Interest expense, net |
|
6,120 |
|
4,444 |
|
Gain on warrant liability |
|
— |
|
(2,601) |
|
Other (income) expense |
|
3,325 |
|
(241) |
|
Income (loss) before taxes |
|
71,216 |
|
(152) |
|
|
|
|
|
|
|
Income tax expense |
|
20,410 |
|
390 |
|
|
|
|
|
|
|
Net income (loss) |
|
50,806 |
|
(542) |
|
|
|
|
|
|
|
Less: net income (loss) attributable to noncontrolling interests |
|
29,589 |
|
(178) |
|
|
|
|
|
|
|
Net income (loss) attributable to Nutex Health Inc. |
|
$ 21,217 |
|
$ (364) |
|
|
|
|
|
|
|
Earnings (loss) per common share |
|
|
|
|
|
Basic |
|
$ 3.74 |
|
$ (0.08) |
|
Diluted |
|
$ 3.33 |
|
$ (0.08) |
|
NUTEX HEALTH INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
|
||||
|
|
|
Three Months Ended March 31, |
||
|
(In thousands) |
|
2025 |
|
2024 |
|
Cash flows from operating activities: |
|
(As Restated) |
|
|
|
Net income (loss) |
|
$ 50,806 |
|
$ (542) |
|
Adjustment to reconcile net income (loss) to net cash from operating activities: |
|
|
|
|
|
Depreciation and amortization |
|
5,092 |
|
4,186 |
|
Gain on warrant liability |
|
— |
|
(2,601) |
|
Stock-based compensation expense |
|
27,642 |
|
49 |
|
Changes to deferred taxes |
|
(2,500) |
|
(95) |
|
Debt accretion expense |
|
253 |
|
365 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
Accounts receivable |
|
(62,633) |
|
(2,909) |
|
Accounts receivable - related party |
|
(656) |
|
(62) |
|
Inventories |
|
(268) |
|
415 |
|
Prepaid expenses and other current assets |
|
(1,378) |
|
796 |
|
Operating right-of-use assets |
|
406 |
|
273 |
|
Accounts payable |
|
10,222 |
|
(1,681) |
|
Accounts payable - related party |
|
1,334 |
|
475 |
|
Operating lease liabilities |
|
(245) |
|
(376) |
|
Accrued arbitration expenses |
|
4,061 |
|
— |
|
Accrued income tax expense |
|
19,598 |
|
— |
|
Accrued expenses and other current liabilities |
|
(769) |
|
4,758 |
|
Net cash from operating activities |
|
50,965 |
|
3,051 |
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
Acquisitions of property and equipment |
|
(64) |
|
(733) |
|
Net cash from investing activities |
|
(64) |
|
(733) |
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
Proceeds from lines of credit |
|
3,864 |
|
— |
|
Proceeds from long-term debt |
|
157 |
|
2,915 |
|
Repayments of lines of credit |
|
(292) |
|
(595) |
|
Repayments of long-term debt |
|
(1,810) |
|
(4,388) |
|
Repayments of finance leases |
|
(1,367) |
|
(968) |
|
Proceeds from common stock issuance, net issuance costs |
|
— |
|
9,203 |
|
Members' distributions |
|
(7,364) |
|
(481) |
|
Net cash from financing activities |
|
(6,812) |
|
5,686 |
|
Net change in cash and cash equivalents |
|
44,089 |
|
8,004 |
|
Cash and cash equivalents - beginning of the period |
|
40,640 |
|
22,002 |
|
Cash and cash equivalents - end of the period |
|
$ 84,729 |
|
$ 30,006 |
Non-GAAP Financial Measures (Unaudited)
EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.
We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.
We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense and any acquisition-related costs and impairments. Interest expense includes interest on lease liabilities, which is a component of total finance lease cost. A reconciliation of net income (loss) to Adjusted EBITDA is included below.
Beginning in the first quarter of 2025, we have updated our presentation of Adjusted EBITDA to separately disclose finance lease payments related to leases under ASC 842. We believe this change provides greater transparency into our operating performance.
Adjusted EBITDA is not intended to serve as an alternative to
|
|
Three Months Ended March 31, |
||||||
|
|
2025 |
|
2024 |
||||
|
Reconciliation of net income (loss) attributable to Nutex |
(As restated, |
|
(As restated, |
|
(Updated) |
|
(Prior) |
|
Net income (loss) attributable to Nutex Health Inc. |
$ 21,217 |
|
$ 21,217 |
|
$ (364) |
|
$ (364) |
|
Depreciation and amortization |
5,092 |
|
5,092 |
|
4,186 |
|
4,186 |
|
Interest expense, net |
6,120 |
|
6,120 |
|
4,444 |
|
4,444 |
|
Income tax expense |
20,410 |
|
20,410 |
|
390 |
|
390 |
|
Allocation to noncontrolling interests |
(1,297) |
|
(1,297) |
|
(1,544) |
|
(1,544) |
|
EBITDA |
51,542 |
|
51,542 |
|
7,112 |
|
7,112 |
|
Gain on warrant liability |
— |
|
— |
|
(2,601) |
|
(2,601) |
|
Finance lease payments(1) |
(6,363) |
|
— |
|
(4,972) |
|
— |
|
Stock-based compensation |
27,642 |
|
27,642 |
|
49 |
|
49 |
|
Adjusted EBITDA |
$ 72,821 |
|
$ 79,184 |
|
$ (412) |
|
$ 4,560 |
|
(1) |
Finance lease payments consist of cash payments for financing leases under ASC 842, which should be deducted from EBITDA. We believe this change is useful to investors to evaluate the ongoing operating performance of our business. |
About Nutex Health Inc.
Headquartered in
The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states.
The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.
Forward-Looking Statements
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Report on Form 10-Q/A for the three months ended March 31, 2025 under the heading "Risk Factors" in Part II, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
View original content:https://www.prnewswire.com/news-releases/nutex-health-reports-restated-first-quarter-2025-financial-results-302619372.html
SOURCE Nutex Health, Inc.